What is described herein are antimicrobial compositions which are defined blends of a 1,2-diol and phenoxyethanol which show broad activity against bacteria, fungi and mold spores. This activity is potentiated by the addition thereto of small amounts of a co-biocide for which the blend acts as a delivery system for the otherwise water-insoluble co-biocide.
|
1. An antimicrobial composition consisting essentially of, by weight, based on the total weight of (a) and (b):
(a) 40-60% of a mixture of 1,2-pentanediol, 1,2-hexanediol and 1,2-octanediol;
(b) 40-60% phenoxyethanol; and
(c) a co-biocide present in an amount us to 10% said co-biocide selected from the group consisting of sorbic acid, benzoic acid, dibromodicyano-butane, 1,2-benzisothiazolin-3-one, and mixtures thereof, wherein said antimicrobial composition is active against at least one of E. coli, Staph aureus, P. aeruginosa, B. cepacia, C. albicans, and A. niger.
2. An antimicrobial composition in accordance with
3. An antimicrobial composition in accordance with
4. An antimicrobial composition in accordance with
5. An antimicrobial composition in accordance with
6. An antimicrobial composition in accordance with
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1. Field of the Invention
This invention relates to antimicrobial compositions, and, more particularly, to a defined blend of a 1,2-diol and phenoxyethanol, optionally with a co-biocide, which compositions show broad activity against bacteria, fungi and mold spores.
2. Description of the Prior Art
Personal care products come in many different forms. They include creams, lotions, pastes, liquids, aerosols, shampoos, gels, wipes, bats, sticks, powders and granules any or all of which are intended for topical application to the skin including the scalp and the mucosa including the lips.
The products are generally designed to have a substantial shelf life. The products need to be manufactured at one site, transported possibly over a considerable distance to a depot or other storage facility prior to further transport to a point of sale. The product may then spend considerable time on a retailer's shelf prior to purchase and further storage by the user whether for individual use or use in, for example, a hotel, workplace, institution or the like. All of such storage will take place under uncontrolled conditions including considerable variation in temperature.
In order to keep bacterial and fungal growth in such products at an acceptable level it is conventional practice for the products to contain a preservative. Many preservatives are available. The appropriate preservative has to be selected with regard to its efficacy and its acceptability to contact with human or animal skin. With regard to its acceptability there are in many countries laws and regulations governing the maximum permitted content of preservative in products intended for human use due to their possible toxic or otherwise harmful effect.
The need to control microbiological growth in personal care products is known to be particularly acute in water based products such as non-ionic oil-in-water emulsions and in pre-impregnated wipes such as baby wipes.
For example, U.S. Pat. No. 6,607,738 described a preservative system of iodopropynyl butyl carbamate (IPBC) and phenoxyethanol (PE) in a weight ratio of 1:90 to 1:400 for use in personal care products.
U.S. Pat. No. 5,516,510 also disclosed deodorizing active ingredients to reduce the unpleasant odor caused by microorganisms which comprised a glycerin monoalkyl ether in combination with an astringent and/or a naturally occurring deodorant.
EP 1206933 described a preservative composition of caprlyl glycol (1,2-octanediol) and iodopropynyl butyl carbamate in a weight ratio of 0.1 to 500.
U.S. Pat. No. 5,733,362 was directed to a bacterial composition of 2-methyl-4,5-trimethylene-4-isothiazoline-3-on; 3-iodo-2-propynyl butyl carbamate and 2-phenoxyethanol.
EP 1238651 described that the activity of preservative mixtures of iodopropynyl butyl carbamate and phenoxyethanol, in a weight ratio of 1:90 to 1:200, preferably 1:100, can be potentiated by adding caprylyl glycol thereto, in a weight ratio of the latter to the mixture of 0.1 to 500, preferably 1:55. Thus the formulation of caprylyl glycol, iodopropynyl butyl carbamate and phenoxyethanol had weight ratios of each of 55:1:100 to 200:1:400, respectively. The personal care formulations contained 0.1-30% caprylyl glycol, preferably 0.5%; with 0.001-1% IPBC, preferably 0.001-0.01%; and with phenoxyethanol of 0.1-3%, preferably 0.5-1%.
JP Application No. 11045504 described an antiseptic microbicide and compositions thereof which contained a 1,2-alkane diol. These compositions effectively reduced the required dosage of conventional antiseptic microbicides such as paraben, benzoic acid and the like. The 1,2-alkane diol therein could be blended with a photosensitizer, benzoic acid or its salt, phenoxyethanol or 4-isopropyl-3-methylphenol. However, there was no disclosure of suitable blends of 1,2-alkane diol and phenoxyethanol at predetermined weight ratios and HLB values, which could deliver water insoluble biocides such as IPBC into aqueous personal care systems at a relatively high concentration of such biocides.
These and other prior art references in this field were concerned with the problem that many are antibacterials such as IPBC have limited aqueous solubility inpersonal care systems; particularly at the high concentrations necessary for effective antimicrobial activity. Thus, at very low concentrations they remain in solution but do not contribute as much activity as desired for these products.
Accordingly, it is desired to provide a blend of 1,2-diol and phenoxyethanol at a predetermined ratio and HLB value which can deliver water insoluble biocides into an aqueous personal care system at relatively high concentrations thereby providing more effective preservative activity in such systems.
What is described herein is an antimicrobial composition which is active against bacteria, yeast and mold spores, consisting essentially of, by wt.
(a) 40-60% of a 1,2-diol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol and 1,2-octanediol;
(b) 40-60% of phenoxyethanol; and
(c) 0-10% of a co-biocide selected from the group consisting of sorbic acid, benzoic acid, dibromodicyanobutane, iodopropynyl butyl carbamate and 1,2-benzisothiazolin-3-one.
A preferred antimicrobial composition of the invention includes (c) sorbic acid and/or 1% iodopropynyl butyl carbamate.
Most preferred antimicrobial compositions herein are those wherein (a) is about 44% and (b) is about 56%.
Also preferred are antimicrobial compositions wherein (c) is sorbic acid present in an amount of about 5-7% of the composition, or IPBC present in an amount of 1.25-1.50%.
Preferred antimicrobial compositions of the invention include those wherein (a) is 41-42%, (b) is 52-53%; and (c) is sorbic acid 5-7%; and (a) is 43.3; (b) is 55.3; and (c) is IPBC 1.4%.
The invention also encompasses personal care products which include the antimicrobial composition described above, preferably wherein the antibacterial composition is present in an amount of 0.1-2% by weight of the product, most preferably 0.5-1.5%.
In accordance with the invention, there is provided herein an antimicrobial composition which is active against bacteria, yeast and mold spores, consisting essentially of, by wt.
(a) 40-60% of a 1,2-diol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol and 1,2-octanediol;
(b) 40-60% of phenoxyethanol; and
(c) 0-10% of a co-biocide selected from the group consisting of sorbic acid, benzoic acid, dibromodicyanobutane, iodopropynyl butyl carbamate and 1,2-benzisothiazolin-3-one.
Preferably the antimicrobial composition includes (c) sorbic acid and/or 1% iodopropynyl butyl carbamate.
Most preferably, the antimicrobial composition includes (a) about 44% and (b) about 56%, and, optionally, (c) is sorbic acid, present in an amount of about 5-7% of the composition, or (c) is IPBC present in an amount of 1.25-1.50%.
Most preferably, it is an antimicrobial composition wherein (a) is 41-42%, (b) is 52-53%; and (c) is sorbic acid 5-7%; most preferably, wherein (a) is 43.3; (b) is 55.3; and (c) is IPBC 1.4%.
Personal care products particularly utilize the antimicrobial composition, preferably, wherein the antibacterial composition is present in an amount of 0.1-2% by weight of the product, most preferably, 0.5-1.5%.
The invention will now be described in more detail by the following challenge test examples on the invention formulations.
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
1.9 × 106 cfu/ml
1.2 × 106 cfu/ml
E. coli 8739
4.6 × 106 cfu/ml
2.1 × 106 cfu/ml
P. aeruginosa 9027
1.7 × 106 cfu/ml
2.1 × 106 cfu/ml
B. cepacia 25416
2.5 × 106 cfu/ml
2.0 × 106 cfu/ml
C. albicans 10231
2.7 × 106 cfu/ml
9.0 × 105 cfu/ml
A. niger 16404
3.0 × 105 cfu/ml
1.0 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.5%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
2.2E5
<10
<10
<10
<10
A. niger 16404
5.5E5
2E4
3.8E2
6E1
6.6E3
USE LEVEL: 1.0%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
1.4E5
<10
<10
<10
<10
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
1.3 × 106 cfu/ml
8.0 × 106 cfu/ml
E. coli 8739
3.9 × 106 cfu/ml
4.8 × 106 cfu/ml
P. aeruginosa 9027
2.5 × 106 cfu/ml
4.7 × 106 cfu/ml
B. cepacia 25416
1.5 × 106 cfu/ml
1.0 × 106 cfu/ml
C. albicans 10231
3.2 × 106 cfu/ml
1.6 × 106 cfu/ml
A. niger 16404
4.0 × 105 cfu/ml
2.6 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.5%
Staph. aureus 6538
1.4E5
<10
<10
<10
<10
E. coli 8739
6.6E3
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
4.0E4
<10
<10
<10
<10
C. albicans 10231
>1E6
8.1E5
5.2E4
<10
>1E4
A. niger 16404
5.9E5
1.9E5
3.5E4
1.2E4
6.9E5
USE LEVEL: 1.0%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
3.4E5
<10
<10
<10
<10
A. niger 16404
6.5E5
2.4E4
1.2E3
9E1
>1E4
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
4.9 × 106 cfu/ml
2.6 × 106 cfu/ml
E. coli 8739
5.6 × 106 cfu/ml
4.3 × 106 cfu/ml
P. aeruginosa 9027
3.1 × 106 cfu/ml
3.2 × 106 cfu/ml
B. cepacia 25416
2.7 × 106 cfu/ml
1.8 × 106 cfu/ml
C. albicans 10231
4.2 × 106 cfu/ml
1.7 × 107 cfu/ml
A. niger 16404
1.9 × 105 cfu/ml
4.0 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.67% (100 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
<10
<10
<10
<10
<10
USE LEVEL: 1.33% (200 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
<10
<10
<10
<10
<10
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
1.2 × 106 cfu/ml
3.7 × 106 cfu/ml
E. coli 8739
3.2 × 106 cfu/ml
3.1 × 106 cfu/ml
P. aeruginosa 9027
3.0 × 106 cfu/ml
4.6 × 106 cfu/ml
B. cepacia 25416
6.0 × 105 cfu/ml
3.2 × 106 cfu/ml
C. albicans 10231
2.8 × 106 cfu/ml
2.4 × 106 cfu/mml
A. niger 16404
7.0 × 105 cfu/ml
4.0 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.67% (100 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
3E1
<10
<10
<10
<10
USE LEVEL: 1.33% (200 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
<10
<10
<10
<10
<10
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
3.7 × 106 cfu/ml
2.9 × 106 cfu/ml
E. coli 8739
3.1 × 106 cfu/ml
5.4 × 106 cfu/ml
P. aeruginosa 9027
4.6 × 106 cfu/ml
3.8 × 106 cfu/ml
B. cepacia 25416
3.2 × 106 cfu/ml
2.9 × 106 cfu/ml
C. albicans 10231
2.4 × 106 cfu/ml
2.2 × 106 cfu/ml
A. niger 16404
4.0 × 105 cfu/ml
2.9 × 105 cfu/ml
48
ASSAY INTERVALS
TEST ORGANISMS
HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.25% (37.5 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
7.1E2
<10
<10
<10
<10
A. niger 16404
4.2E4
3.4E3
1.2E2
2E1
6.7E2
USE LEVEL: 0.5% (75 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
<10
<10
<10
<10
2E1
(replate <10)
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
4.9 × 106 cfu/ml
4.8 × 106 cfu/ml
E. coli 8739
3.5 × 106 cfu/ml
3.1 × 106 cfu/ml
P. aeruginosa 9027
4.0 × 106 cfu/ml
3.0 × 106 cfu/ml
B. cepacia 25416
4.0 × 106 cfu/ml
2.2 × 106 cfu/ml
C. albicans 10231
3.5 × 106 cfu/ml
8.0 × 105 cfu/ml
A. niger 16404
2.7 × 106 cfu/ml
1.8 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.25% (37.5 ppm BIT)
Staph. aureus 6538
2E1
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
2E1
<10
<10
<10
<10
C. albicans 10231
>1E6
7.2E2
1E2
<10
>1E4
A. niger 16404
3.9E5
2.4E5
1.9E5
1.6E5
2.5E5
USE LEVEL: 0.50% (75 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
4.4E4
2E3
5E1
<10
3.5E3
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
3.6 × 106 cfu/ml
2.8 × 106 cfu/ml
E. coli 8739
5.8 × 106 cfu/ml
3.5 × 106 cfu/ml
P. aeruginosa 9027
4.0 × 106 cfu/ml
3.2 × 106 cfu/ml
B. cepacia 25416
3.0 × 106 cfu/ml
1.8 × 106 cfu/ml
C. albicans 10231
2.7 × 106 cfu/ml
1.7 × 106 cfu/ml
A. niger 16404
1.3 × 106 cfu/ml
4.9 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.50% (75 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
<10
<10
<10
<10
<10
USE LEVEL: 0.67% (100 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
<10
<10
<10
<10
<10
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
3.6 × 106 cfu/ml
2.8 × 106 cfu/ml
E. coli 8739
5.8 × 106 cfu/ml
3.5 × 106 cfu/ml
P. aeruginosa 9027
4.0 × 106 cfu/mml
3.2 × 106 cfu/ml
B. cepacia 25416
3.0 × 106 cfu/ml
1.8 × 106 cfu/ml
C. albicans 10231
2.7 × 106 cfu/ml
1.7 × 106 cfu/ml
A. niger 16404
1.3 × 106 cfu/ml
4.9 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.3% (75 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
5.8E3
2E1
<10
<10
<10
A. niger 16404
1.8E2
<10
<10
<10
<10
USE LEVEL: 0.4% (100 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
<10
<10
<10
<10
<10
1,2-Octanediol/Phenoxyethanol (40/60)/1.5% BIT
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
3.0 × 106 cfu/ml
2.8 × 106 cfu/ml
E. coli 8739
5.8 × 106 cfu/ml
3.5 × 106 cfu/ml
P. aeruginosa 9027
4.0 × 106 cfu/ml
3.2 × 106 cfu/ml
B. cepacia 25416
3.0 × 106 cfu/ml
1.8 × 106 cfu/ml
C. albicans 10231
2.7 × 106 cfu/ml
1.7 × 106 cfu/ml
A. niger 16404
1.3 × 106 cfu/ml
4.9 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.50% (75 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
8E1
<10
<10
<10
<10
USE LEVEL: 0.67% (100 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
<10
<10
<10
<10
<10
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
3.0 × 106 cfu/ml
2.8 × 106 cfu/ml
E. coli 8739
5.8 × 106 cfu/ml
3.5 × 106 cfu/ml
P. aeruginosa 9027
4.0 × 106 cfu/ml
3.2 × 106 cfu/ml
B. cepacia 25416
3.0 × 106 cfu/ml
1.8 × 106 cfu/ml
C. albicans 10231
2.7 × 106 cfu/ml
1.7 × 106 cfu/ml
A. niger 16404
1.3 × 106 cfu/ml
4.9 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.30% (75 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
1E4
8.6E2
2.1E2
3E1
8.3E2
USE LEVEL: 0.40% (100 ppm BIT)
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
1E1
<10
<10
<10
<10
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
1.3 × 106 cfu/ml
8.0 × 106 cfu/ml
E. coli 8739
3.9 × 106 cfu/ml
4.8 × 106 cfu/ml
P. aeruginosa 9027
2.5 × 106 cfu/ml
4.7 × 106 cfu/ml
B. cepacia 25416
1.5 × 106 cfu/ml
1.0 × 106 cfu/ml
C. albicans 10231
3.2 × 106 cfu/ml
1.6 × 106 cfu/ml
A. niger 16404
4.0 × 105 cfu/ml
2.6 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.5%
Staph. aureus 6538
1.1E2
<10
<10
<10
<10
E. co1i 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
8E3
7E4
1.1E5
C. albicans 10231
>1E6
3.1E4
<10
<10
>1E4
A. niger 16404
8.3E5
4E1
<10
<10
1E1
USE LEVEL: 1.0%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
1.2E4
<10
<10
<10
<10
A. niger 16404
3E5
<10
<10
<10
<10
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
6.9 × 106 cfu/ml
1.8 × 106 cfu/ml
E. coli 8739
7.8 × 106 cfu/ml
3.5 × 106 cfu/ml
P. aeruginosa 9027
5.1 × 106 cfu/ml
1.3 × 106 cfu/ml
B. cepacia 25416
2.2 × 106 cfu/ml
7.0 × 106 cfu/ml
C. albicans 10231
3.7 × 106 cfu/ml
6.0 × 107 cfu/ml
A. niger 16404
1.8 × 105 cfu/ml
8.0 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.50%
Staph. aureus 6538
1E1
<10
<10
<10
<10
E. coli 8739
6E1
<10
<10
<10
<10
P. aeruginosa 9027
1E2
<10
<10
<10
<10
B. cepacia 254l6
5.8E4
<10
<10
<10
<10
C. albicans 10231
>1E6
1.7E5
2E1
<10
>1E4
A. niger 16404
1E5
5.8E4
3E4
6E3
3.9E5
USE LEVEL: 1.0%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
3E4
<10
<10
<10
<10
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
6.9 × 106 cfu/ml
1.8 × 106 cfu/ml
E. coli 8739
7.8 × 106 cfu/ml
3.5 × 106 cfu/ml
P. aeruginosa 9027
5.1 × 106 cfu/ml
1.3 × 106 cfu/ml
B. cepacia 25416
2.2 × 106 cfu/ml
7.0 × 106 cfu/ml
C. albicans 10231
3.7 × 106 cfu/ml
6.0 × 107 cfu/ml
A. niger 16404
1.8 × 105 cfu/ml
8.0 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.5%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
8E1
<10
<10
<10
2E1
C. albicans 10231
>1E6
1.4E4
<10
<10
<10
A. niger 16404
2.1E5
5.5E4
8E3
3E3
3.4E5
USE LEVEL: 1.0%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
8E3
<10
<10
<10
<10
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
6.9 × 106 cfu/ml
1.8 × 106 cfu/ml
E. coli 8739
7.8 × 106 cfu/ml
3.5 × 106 cfu/ml
P. aeruginosa 9027
5.1 × 106 cfu/ml
1.3 × 106 cfu/ml
B. cepacia 25416
2.2 × 106 cfu/ml
7.0 × 106 cfu/ml
C. albicans 10231
3.7 × 106 cfu/ml
6.0 × 107 cfu/ml
A. niger 16404
1.8 × 105 cfu/ml
8.0 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.50%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
>1E6
2E4
<10
<10
>1E4
A. niger 16404
1.8E5
1.1E5
1.2E3
2E2
>1E4
USE LEVEL: 1.0%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
6E3
<10
<10
<10
7E1
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
2.9 × 106 cfu/ml
2.5 × 105 cfu/ml
E. coli 8739
4.7 × 106 cfu/ml
3.4 × 106 cfu/ml
P. aeruginosa 9027
4.9 × 106 cfu/ml
1.2 × 106 cfu/ml
B. cepacia 25416
5.3 × 106 cfu/ml
1.1 × 106 cfu/ml
C. albicans 10231
1.0 × 106 cfu/ml
1.1 × 106 cfu/ml
A. niger 16404
7.0 × 105 cfu/ml
4.4 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.5%
Staph. aureus 6538
7E1
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
4E4
<10
<10
<10
1E1
A. niger 16404
2.3E5
2.3E4
2.5E2
2E1
>1E4
USE LEVEL: 1.0%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
3E4
<10
<10
<10
<10
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
2.5 × 106 cfu/ml
2.5 × 106 cfu/ml
E. coli 8739
6.0 × 106 cfu/ml
2.9 × 106 cfu/ml
P. aeruginosa 9027
5.7 × 106 cfu/ml
2.3 × 106 cfu/ml
B. cepacia 25416
3.4 × 106 cfu/ml
1.5 × 106 cfu/ml
C. albicans 10231
2.9 × 106 cfu/ml
1.1 × 106 cfu/mkl
A. niger 16404
5.1 × 105 cfu/ml
2.8 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.25%
Staph. aureus 6538
1.1E6
1.6E3
<10
<10
>1E4
E. coli 8739
2E2
<10
<10
<10
<10
P. aeruginosa 9027
3E1
3E3
4E1
1E2
>1E4
B. cepacia 25416
>1E6
>1E6
4.3E5
1.8E5
>1E6
C. albicans 10231
7.9E5
1.2E5
4.1E2
2.2E2
>1E4
A. niger 16404
1.8E5
3.2E5
3.3E5
1.4E5
5.1E5
USE LEVEL: 0.50%
Staph. aureus 6538
9.8E4
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
2.7E5
<10
<10
<10
<10
C. albicans 10231
3.8E5
2E2
<10
<10
8E1
A. niger 16404
2.6E5
3.3E5
1.7E3
8E2
>1E4
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
2.5 × 106 cfu/ml
2.5 × 106 cfu/ml
E. coli 8739
6.0 × 106 cfu/ml
2.9 × 106 cfu/ml
P. aeruginosa 9027
5.7 × 106 cfu/ml
2.3 × 106 cfu/ml
B. cepacia 25416
3.4 × 106 cfu/ml
1.5 × 106 cfu/ml
C. albicans 10231
2.9 × 106 cfu/ml
1.1 × 106 cfu/mkl
A. niger 16404
5.1 × 105 cfu/ml
2.8 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.5%
Staph. aureus 6538
2.6E5
<10
<10
<10
<10
E. coli 8739
2.2E4
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
2.6E5
6E3
<10
<10
2.9E3
C. albicans 10231
>1E6
>1E6
4.8E4
7.1E2
9.3E5
A. niger 16404
6.8E5
4.8E5
1.4E5
>1E4
6.2E5
USE LEVEL: 1.0%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
1E2
<10
<10
<10
<10
C. albicans 10231
>1E6
2.8E4
<10
<10
<10
A. niger 16404
3.8E5
3.5E5
1.3E4
2.9E2
5.3E4
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
1.8 × 106 cfu/ml
1.0 × 106 cfu/ml
E. coli 8739
3.5 × 106 cfu/ml
3.6 × 106 cfu/ml
P. aeruginosa 9027
1.3 × 106 cfu/ml
2.9 × 106 cfu/ml
B. cepacia 25416
7.0 × 106 cfu/ml
3.0 × 106 cfu/ml
C. albicans 10231
6.0 × 105 cfu/ml
2.1 × 106 cfu/ml
A. niger 16404
8.0 × 105 cfu/ml
2.8 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 0.5%
Staph. aureus 6538
1.3E4
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 2 5416
1.9E5
<10
<10
<10
<10
C. albicans 10231
3E5
3.3E3
<10
<10
9.7E2
A. niger 16404
6.8E5
6E4
3.3E4
1.1E4
6E4
USE LEVEL: 1.0%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
3.8E2
<10
<10
<10
<10
A. niger 16404
4.9E4
1.4E4
1.7E2
1.3E2
6.7E3
REINOCULUM
TEST ORGANISMS
INOCULUM (0 hours)
(21 days)
Staph aureus 6538
3.6 × 106 cfu/ml
1.6 × 106 cfu/ml
E. coli 8739
4.0 × 106 cfu/ml
2.2 × 106 cfu/ml
P. aeruginosa 9027
4.4 × 106 cfu/ml
1.7 × 106 cfu/ml
B. cepacia 25416
3.0 × 106 cfu/ml
1.7 × 106 cfu/ml
C. albicans 10231
4.2 × 106 cfu/ml
9.3 × 105 cfu/ml
A. niger 16404
9.0 × 105 cfu/ml
2.6 × 105 cfu/ml
ASSAY INTERVALS
TEST ORGANISMS
48 HRS
7 D
14 D
21 D
28 D
USE LEVEL: 1.0%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
<10
<10
<10
<10
<10
USE LEVEL: 1.8%
Staph. aureus 6538
<10
<10
<10
<10
<10
E. coli 8739
<10
<10
<10
<10
<10
P. aeruginosa 9027
<10
<10
<10
<10
<10
B. cepacia 25416
<10
<10
<10
<10
<10
C. albicans 10231
<10
<10
<10
<10
<10
A. niger 16404
<10
<10
<10
<10
<10
Merianos, John J., Garelick, Paul, Lindstrom, Susan M.
| Patent | Priority | Assignee | Title |
| 8519010, | Apr 08 2004 | ISP Investments Inc. | Antimicrobial compositions |
| Patent | Priority | Assignee | Title |
| 5428050, | Apr 28 1994 | ISP CHEMICAL PRODUCTS, INC | Synergistic water soluble preservative compositions of biocidal mixtures |
| 5516510, | Nov 26 1992 | Schulke & Mayr GmbH | Deodorizing active ingredients |
| 5733362, | Dec 02 1996 | TROY TECHNOLOGY CORPORATION, INC | Synergistic bactericide |
| 6607738, | Apr 22 1998 | CLARIANT UK LTD ; CLARIANT CHEMICALS LIMITED | Chemical composition |
| 7115641, | Feb 04 2003 | TROY TECHNOLOGY II, INC | Antimicrobial oxazolidine/iodopropynyl-butyl carbamate composition containing less than 0.1wt% free formaldehyde |
| 7582681, | Feb 19 2002 | SYMRISE AG | Synergistic mixtures of 1,2-alkane diols |
| DE10206759, | |||
| EP1206933, | |||
| EP1238651, | |||
| JP11322591, | |||
| JP2003286153, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Apr 06 2004 | MERIANOS, JOHN J | ISP Investments Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 015194 | /0399 | |
| Apr 06 2004 | GARELICK, PAUL | ISP Investments Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 015194 | /0399 | |
| Apr 06 2004 | LINDSTROM, SUSAN M | ISP Investments Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 015194 | /0399 | |
| Apr 08 2004 | ISP Investments Inc. | (assignment on the face of the patent) | / | |||
| Aug 23 2011 | Ashland Licensing and Intellectual Property LLC | The Bank of Nova Scotia, as Administrative Agent | SECURITY AGREEMENT | 026918 | /0052 | |
| Aug 23 2011 | Hercules Incorporated | The Bank of Nova Scotia, as Administrative Agent | SECURITY AGREEMENT | 026918 | /0052 | |
| Aug 23 2011 | Aqualon Company | The Bank of Nova Scotia, as Administrative Agent | SECURITY AGREEMENT | 026918 | /0052 | |
| Aug 23 2011 | ISP INVESTMENT INC | The Bank of Nova Scotia, as Administrative Agent | SECURITY AGREEMENT | 026918 | /0052 | |
| Aug 23 2011 | JPMORGAN CHASE BANK, N A F K A THE CHASE MANHATTAN BANK | ISP CAPITAL, INC | PATENT RELEASE | 026930 | /0774 | |
| Aug 23 2011 | JPMORGAN CHASE BANK, N A F K A THE CHASE MANHATTAN BANK | ISP CHEMICAL PRODUCTS, INC | PATENT RELEASE | 026930 | /0774 | |
| Aug 23 2011 | JPMORGAN CHASE BANK, N A F K A THE CHASE MANHATTAN BANK | VERONA, INC | PATENT RELEASE | 026930 | /0774 | |
| Mar 14 2013 | THE BANK OF NOVA SCOTIA | ISP Investments Inc | RELEASE OF PATENT SECURITY AGREEMENT | 030025 | /0320 | |
| Mar 14 2013 | THE BANK OF NOVA SCOTIA | Hercules Incorporated | RELEASE OF PATENT SECURITY AGREEMENT | 030025 | /0320 | |
| Mar 14 2013 | THE BANK OF NOVA SCOTIA | Ashland Licensing and Intellectual Property LLC | RELEASE OF PATENT SECURITY AGREEMENT | 030025 | /0320 | |
| Mar 14 2013 | THE BANK OF NOVA SCOTIA | Aqualon Company | RELEASE OF PATENT SECURITY AGREEMENT | 030025 | /0320 | |
| Aug 18 2016 | ISP Investments Inc | ISP Investments LLC | CONVERSION | 041556 | /0499 | |
| Jun 30 2017 | AVOCA, INC | The Bank of Nova Scotia, as Administrative Agent | SECURITY AGREEMENT | 043084 | /0753 | |
| Jun 30 2017 | HERCULES LLC | The Bank of Nova Scotia, as Administrative Agent | SECURITY AGREEMENT | 043084 | /0753 | |
| Jun 30 2017 | ISP Investments LLC | The Bank of Nova Scotia, as Administrative Agent | SECURITY AGREEMENT | 043084 | /0753 | |
| Jun 30 2017 | PHARMACHEM LABORATORIES, INC | The Bank of Nova Scotia, as Administrative Agent | SECURITY AGREEMENT | 043084 | /0753 | |
| Jan 10 2020 | THE BANK OF NOVA SCOTIA | AVOCA LLC | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 051557 | /0504 | |
| Jan 10 2020 | THE BANK OF NOVA SCOTIA | ISP Investments LLC | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 051557 | /0504 | |
| Jan 10 2020 | THE BANK OF NOVA SCOTIA | PHARMACHEM LABORATORIES LLC | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 051557 | /0504 | |
| Jan 10 2020 | THE BANK OF NOVA SCOTIA | HERCULES LLC | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 051557 | /0504 |
| Date | Maintenance Fee Events |
| Nov 03 2014 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Nov 05 2018 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Nov 03 2022 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
| Date | Maintenance Schedule |
| May 03 2014 | 4 years fee payment window open |
| Nov 03 2014 | 6 months grace period start (w surcharge) |
| May 03 2015 | patent expiry (for year 4) |
| May 03 2017 | 2 years to revive unintentionally abandoned end. (for year 4) |
| May 03 2018 | 8 years fee payment window open |
| Nov 03 2018 | 6 months grace period start (w surcharge) |
| May 03 2019 | patent expiry (for year 8) |
| May 03 2021 | 2 years to revive unintentionally abandoned end. (for year 8) |
| May 03 2022 | 12 years fee payment window open |
| Nov 03 2022 | 6 months grace period start (w surcharge) |
| May 03 2023 | patent expiry (for year 12) |
| May 03 2025 | 2 years to revive unintentionally abandoned end. (for year 12) |